HUP0203458A3 - Nociceptin receptor orl-1 agonists for use in treating cough and pharmaceutical compositions containing them - Google Patents

Nociceptin receptor orl-1 agonists for use in treating cough and pharmaceutical compositions containing them

Info

Publication number
HUP0203458A3
HUP0203458A3 HU0203458A HUP0203458A HUP0203458A3 HU P0203458 A3 HUP0203458 A3 HU P0203458A3 HU 0203458 A HU0203458 A HU 0203458A HU P0203458 A HUP0203458 A HU P0203458A HU P0203458 A3 HUP0203458 A3 HU P0203458A3
Authority
HU
Hungary
Prior art keywords
agonists
pharmaceutical compositions
compositions containing
treating cough
nociceptin receptor
Prior art date
Application number
HU0203458A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HUP0203458A2 publication Critical patent/HUP0203458A2/hu
Publication of HUP0203458A3 publication Critical patent/HUP0203458A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HU0203458A 1999-07-26 2000-01-26 Nociceptin receptor orl-1 agonists for use in treating cough and pharmaceutical compositions containing them HUP0203458A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/359,771 US6262066B1 (en) 1998-07-27 1999-07-26 High affinity ligands for nociceptin receptor ORL-1
PCT/US2000/001853 WO2001007050A1 (en) 1999-07-26 2000-01-26 Nociceptin receptor orl-1 agonists for use in treating cough

Publications (2)

Publication Number Publication Date
HUP0203458A2 HUP0203458A2 (hu) 2003-02-28
HUP0203458A3 true HUP0203458A3 (en) 2004-01-28

Family

ID=23415204

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203458A HUP0203458A3 (en) 1999-07-26 2000-01-26 Nociceptin receptor orl-1 agonists for use in treating cough and pharmaceutical compositions containing them

Country Status (13)

Country Link
US (4) US6262066B1 (US06262066-20010717-C00176.png)
EP (1) EP1200087A1 (US06262066-20010717-C00176.png)
JP (1) JP2003505420A (US06262066-20010717-C00176.png)
CN (1) CN1374865A (US06262066-20010717-C00176.png)
AU (1) AU2629800A (US06262066-20010717-C00176.png)
BR (1) BR0012801A (US06262066-20010717-C00176.png)
CA (1) CA2379398A1 (US06262066-20010717-C00176.png)
HK (1) HK1042236A1 (US06262066-20010717-C00176.png)
HU (1) HUP0203458A3 (US06262066-20010717-C00176.png)
MX (1) MXPA02001033A (US06262066-20010717-C00176.png)
NO (1) NO20020392L (US06262066-20010717-C00176.png)
WO (1) WO2001007050A1 (US06262066-20010717-C00176.png)
ZA (1) ZA200200275B (US06262066-20010717-C00176.png)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
US7485650B2 (en) * 1998-07-27 2009-02-03 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
DE60033071T2 (de) * 1999-12-06 2007-08-23 Euro-Celtique S.A. Triazospiroverbindungen mit nociceptin-rezeptoraffinität
JP2003524634A (ja) * 1999-12-06 2003-08-19 ユーロ−セルティーク，エス．エイ． ノシセプチン受容体親和性を有するベンズイミダゾール化合物
DE20005049U1 (de) * 2000-03-20 2000-05-18 Dewert Antriebs Systemtech Elektromotorische Antriebseinheit
EP1392687B1 (en) * 2001-04-10 2017-02-01 Janssen Pharmaceuticals, Inc. 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
PE20021081A1 (es) * 2001-04-12 2002-12-18 Pharmacopeia Drug Discovery Aril y biaril piperidinas con actividad moduladora mch
EP1385514B9 (en) 2001-04-18 2009-08-12 Euro-Celtique S.A. Spiroindene and spiroindane compounds
CA2444634C (en) 2001-04-18 2011-06-07 R. Richard Goehring Spiropyrazole compounds
MXPA03009600A (es) 2001-04-18 2004-04-02 Euro Celtique Sa Analogos de nociceptina.
CN100441182C (zh) 2001-04-18 2008-12-10 欧罗赛铁克股份有限公司 伤害感受肽化合物
EP1385518B1 (en) 2001-04-18 2008-08-06 Euro-Celtique S.A. Benzimidazolone compounds
WO2002088089A1 (fr) * 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
WO2002100861A1 (en) * 2001-06-13 2002-12-19 Akzo Nobel N.V. 1-(3-phenyloxypropyl)piperidine derivatives
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
FR2827281B1 (fr) * 2001-07-16 2003-12-19 Sanofi Synthelabo Procede pour la preparation de la 4-methylamino-4-phenylpiperidine
FR2827282B1 (fr) * 2001-07-16 2004-08-13 Sanofi Synthelabo Procede pour la preparation de 4-amino-4-phenylpiperidines
US7049287B2 (en) * 2001-10-09 2006-05-23 Synvax, Inc. Nociceptin-based analgesics
TWI317360B (en) * 2001-11-07 2009-11-21 Schering Corp Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
AR037364A1 (es) 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
US7652039B2 (en) 2002-05-17 2010-01-26 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious disease
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
CN1684701B (zh) * 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
JP2006502239A (ja) * 2002-08-29 2006-01-19 アストラゼネカ・アクチエボラーグ ナフトアミド誘導体およびその使用
BR0306309A (pt) * 2002-09-09 2004-10-19 Janssen Pharmaceutica Nv Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1
US7045527B2 (en) 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
UY28417A1 (es) * 2003-07-17 2005-02-28 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
TW200519101A (en) * 2003-09-25 2005-06-16 Solvay Pharm Bv Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
EA013435B1 (ru) * 2003-10-14 2010-04-30 Глэксо Груп Лимитед Антагонисты мускариновых ацетилхолиновых рецепторов
CN1897947A (zh) * 2003-10-17 2007-01-17 葛兰素集团有限公司 蕈毒碱乙酰胆碱受体拮抗剂
JPWO2005037269A1 (ja) * 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2006031788A2 (en) * 2004-09-15 2006-03-23 Schering-Plough Ltd. Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006130416A2 (en) * 2005-06-02 2006-12-07 Janssen Pharmaceutica, N.V. Novel 3-spirocyclic indolyl derivatives useful as orl-1 receptor modulators
AU2006270084B2 (en) 2005-07-18 2011-08-25 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US20080234315A1 (en) * 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1943250A1 (en) 2005-09-09 2008-07-16 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
PE20071159A1 (es) * 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
WO2007085357A1 (en) * 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
CA2654262A1 (en) * 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
EP2063889A4 (en) * 2006-09-07 2009-09-16 Merck & Co Inc SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
AU2007325355A1 (en) * 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl) -1,3,8-triaza-spiro[4.5]decan-4-one
ES2353448T3 (es) 2007-01-16 2011-03-02 Purdue Pharma L.P. Piperidinas heterocíclico-sustituidas como ligandos de orl-1.
BRPI0808025A2 (pt) * 2007-03-01 2014-06-24 Mitsubishi Tanabe Pharma Corp Composto de benzimidazol e uso farmacêutico do mesmo
MX2009011006A (es) * 2007-04-09 2009-11-02 Janssen Pharmaceutica Nv Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
MY150602A (en) * 2007-08-31 2014-01-30 Purdue Pharma Lp Subtituted-quinoxaline-type piperidine compounds and the uses thereof
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑
MY153948A (en) 2008-07-21 2015-04-15 Purdue Pharma Lp Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
KR20110086769A (ko) * 2008-11-23 2011-07-29 화이자 인코포레이티드 베타 세크레타제 억제제로서의 락탐
ITNA20090026A1 (it) * 2009-05-14 2010-11-15 Agostino Bruno D Agonisti del recettore nop e loro usi terapeutici
WO2011017122A1 (en) 2009-07-27 2011-02-10 Trigemina Inc. Methods for treatment of pain
WO2011099980A1 (en) 2010-02-12 2011-08-18 The Johns Hopkins University Use of the lactosylceramide synthase isoform b1, 4galt-v as a biomarker for cancer
MY169449A (en) 2011-04-01 2019-04-11 Astrazeneca Ab Therapeutic treatment
RU2640485C2 (ru) 2011-11-30 2018-01-09 Астразенека Аб Комбинированное лечение рака
US9290488B2 (en) 2011-12-01 2016-03-22 Purdue Pharma L.P. Azetidine-substituted quinoxalines as opioid receptor like-1 modulators
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
JPWO2013164954A1 (ja) * 2012-05-01 2015-12-24 住友化学株式会社 ピペリジン化合物及びその有害生物防除用途
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2014102592A2 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
JP6359560B2 (ja) * 2012-12-31 2018-07-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 複素環式化合物及びその使用方法
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
EP4331670A2 (en) 2015-01-07 2024-03-06 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
US10751335B2 (en) 2016-03-15 2020-08-25 The Scripps Research Institute Signaling-biased mu opioid receptor agonists
GB201706162D0 (en) 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
EP4345096A1 (en) 2021-07-14 2024-04-03 Yichang Humanwell Pharmaceutical Co., Ltd. Piperidine derivative, and pharmaceutical composition thereof, preparation method therefor, and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633914A (US06262066-20010717-C00176.png) * 1962-06-22
GB1052302A (US06262066-20010717-C00176.png) 1963-04-22
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3311264A (en) 1964-12-14 1967-03-28 Arthur W Cayer Measuring and dispensing device
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
US4521537A (en) 1982-08-20 1985-06-04 Hoechst-Roussel Pharmaceuticals Incorporated Spiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine and -3'-pyrrolidine] compounds and their use as antihypertensive agents
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
JPS61225167A (ja) 1985-03-28 1986-10-06 Yoshitomi Pharmaceut Ind Ltd ベンゾ〔ｇ〕キノリン誘導体
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE19875039I2 (de) 1990-10-12 2003-05-22 Merck Frosst Canada Inc Ungesaettigte Hydroxyalkylchinolinsaeuren als Leukotrien-Antagonisten
GB9100505D0 (en) 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
US5583000A (en) 1991-09-03 1996-12-10 The Regents Of The University Of California Protease-binding compounds and methods of use
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5472964A (en) 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
AU691829B2 (en) * 1993-07-16 1998-05-28 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
US5495052A (en) * 1994-09-29 1996-02-27 Arco Chemical Technology, L.P. Process for producing enantiomerically enriched guaifenesin
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE19519245C2 (de) 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0742208A1 (en) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
CA2245162A1 (en) 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composition
CA2226058C (en) 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
EP0921125B1 (en) 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
PT1049689E (pt) 1998-01-19 2002-09-30 Pfizer Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
DE69923744T2 (de) * 1998-10-23 2006-02-23 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
TWI317360B (en) * 2001-11-07 2009-11-21 Schering Corp Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1

Also Published As

Publication number Publication date
ZA200200275B (en) 2003-06-25
AU2629800A (en) 2001-02-13
HK1042236A1 (zh) 2002-08-09
EP1200087A1 (en) 2002-05-02
US6716846B2 (en) 2004-04-06
US20030073690A1 (en) 2003-04-17
US6262066B1 (en) 2001-07-17
NO20020392L (no) 2002-03-25
CN1374865A (zh) 2002-10-16
CA2379398A1 (en) 2001-02-01
US20010011092A1 (en) 2001-08-02
JP2003505420A (ja) 2003-02-12
US6455527B2 (en) 2002-09-24
BR0012801A (pt) 2002-05-07
NO20020392D0 (no) 2002-01-25
HUP0203458A2 (hu) 2003-02-28
WO2001007050A1 (en) 2001-02-01
MXPA02001033A (es) 2002-08-20
US7094784B2 (en) 2006-08-22
US20040152707A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
HUP0203458A3 (en) Nociceptin receptor orl-1 agonists for use in treating cough and pharmaceutical compositions containing them
HUP0103840A3 (en) New substituted pyperidine-derivatives for nociceptin receptor orl-1, pharmaceutical compositions containing them and their use
HUP0203638A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use
IL163864A0 (en) Improvement in apparatus for and methods of damagerepair
HUP0203895A3 (en) Substituted azaindoles and pharmaceutical compositions containing them and their use
EP1144043A4 (en) LIQUID DELIVERY METHODS AND DEVICE
HUP0201033A3 (en) Glucagon antagonists/inverse agonists, process for their preparation and their use
HUP0204515A3 (en) 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203528A3 (en) Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use
IL152417A0 (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
HUP0102658A3 (en) Pharmaceutical composition containing opioid agonist and antagonist combination
EP1244447A4 (en) NOVEL METHODS AND NOVEL COMPOSITIONS COMPRISING OPIOIDS AND OPIOID ANTAGONISTS
HUP0300782A3 (en) Nitrogen-containing heterocyclic caspase inhibitors process for their preparation, pharmaceutical compositions containing them and use thereof
HUP0303016A3 (en) Xanthine phosphodiesterase v inhibitors, process for their preparation and pharmaceutical compositions containing them and their use
HUP0202338A2 (en) Pharmaceutical composition containing fenofibrate and preparation method
HUP0202329A2 (en) Pharmaceutical composition in unit form containing acetylsalycilic acid and clopidogrel hydrogenosulphate
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
HK1035146A1 (en) Pharmaceutical composition for use in emergency treatment and preparation method thereof
HUP0400349A3 (en) Ccr5 antagonists useful for treating aids and pharmaceutical compositions containing them
IL149495A0 (en) Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
HUP0105481A3 (en) Pharmaceutical compositions containing clarithromycin and process for their preparation and their use
HUP0203121A3 (en) Pharmaceutical composition containing substituted benzimidazoles and its use
HUP0200134A3 (en) Controlled release formulation for treating copd and process for its preparation
AU2962200A (en) Use of agonists or antagonists of mip-3a in therapy
PL352280A1 (en) Derivatives of naphthyridine, method of making same, use of same and pharmaceutical compositions containing these derivatives